EX-4, a common glucagon-like peptide-1 receptor agonist, has been confirmed to possess excellent effects on treating patients with T2DM by significantly reducing HbA1c content compared to basal insulins (Singh et al., 2017). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.